Abstract Non-small cell lung cancer (NSCLC) harboring KRASG12D mutations and TP53 deficiency is associated with poor clinical outcomes, and effective therapeutic options remain limited. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have made tremendous advances in lung cancer therapy over the last few years. Despite this, only a subset of patients receives durable clinical responses with PD-1/PD-L1 monotherapy.
Mengdi Wu
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Mengdi
Contact Mengdi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack